**FREEDOM OF INFORMATION REQUEST**

**FOI request into commissioning services that deliver high quality VTE prevention**

**Name:** Brendon Prescott

**Position:** Deputy Chief Nurse

**Clinical Commissioning Group:** NHS South Sefton CCG and NHS Southport and Formby CCG

**Email:** brendon.prescott@southseftonccg.nhs.uk

*Please note that additional paper or electronic copies are available on request from the All-Party Parliamentary Thrombosis Group secretariat*

**Please return your completed response to the All-Party Parliamentary Thrombosis Group secretariat:**

Zain Razvi

All-Party Parliamentary Thrombosis Group Secretariat

c/o Four Public Affairs

20 St Thomas Street

London

SE1 9BF

Email: [Zain.Razvi@fourcommunications.com](mailto:Zain.Razvi@fourcommunications.com)

Telephone: 020 3697 4384

Under the Freedom of Information Act 2000, the All-Party Parliamentary Thrombosis Group writes to request the following information:

**Venous thromboembolism (VTE)** **is a collective term referring to deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is defined by the following ICD-10 codes: I80.0-I80.3, I80.8-I80.9, I82.9, O22.2 – O22.3, O87.0 – O87.1, I26.0, and I26.9.**

**QUESTION 1 – QUALITY ASSURANCE**

VTE prevention has been recognised as a clinical priority for the NHS by the National Quality Board and the NHS Leadership Team. It has been identified as the most important patient safety practice in our hospitals, and VTE-specific indicators feature in both the NHS Outcomes Framework and the CCG Outcomes Indicator Set.

The delivery of high quality VTE prevention should automatically underpin the majority of admissions due to medical illness or surgery as part of the providers’ duty to deliver care in a safe environment. Commissioners should ensure that this duty is clearly mandated through local service contracts.

1. **Has your CCG clearly mandated in its providers’ service contracts that failure to comply with best practice in VTE prevention will result in consequences imposed by your CCG?** (*Best practice in VTE Prevention as defined by NICE Quality Standard 3: VTE Prevention, NICE Clinical Guideline 92, the VTE risk assessment National Quality Requirement, and NHS Standard Contract Service Condition 22) (Tick a box)*

|  |  |
| --- | --- |
| Yes |  |
| No |  |

**QUESTION 2 – VTE Risk Assessment and Root Cause Analysis**

The VTE risk assessment National Quality Requirement stipulates that Trusts must risk assess at least 95 per cent of all in patient service users. Until 2016/17, failure to comply with this requirement resulted in a nationally set commissioning sanction.

1. **Has your CCG agreed a local penalty for failure to comply with the VTE risk assessment National Quality Requirement?** *(Tick a box)*

|  |  |
| --- | --- |
| Yes |  |
| No |  |

**If yes to the above, please describe the local penalty that has been agreed:**

|  |
| --- |
| Vi individual Quality Compliance Schedules |

1. **Between 1 April 2017 and 31 March 2018, has your CCG imposed a penalty on providers that fail to comply with the VTE risk assessment National Quality Requirement?** *(Tick a box)*

|  |  |
| --- | --- |
| Yes |  |
| No |  |

**If ‘Yes’, please specify which providers your CCG has imposed a penalty on between 1 April 2017 and 31 March 2018 and, if the penalty was a financial sanction, please indicate the value of the sanctions imposed:**

|  |  |
| --- | --- |
| **Name of provider** | **Value of sanctions** |
|  |  |

Furthermore, according to Service Condition 22 of the NHS Standard Contract 2017/19, the provider must:

“Perform Root Cause Analysis of all confirmed cases of pulmonary embolism and deep vein thrombosis acquired by Service Users while in hospital (both arising during a current hospital stay and where there is a history of hospital admission within the last 3 months, but not in respect of Service Users admitted to hospital with a confirmed venous thromboembolism but no history of an admission to hospital within the previous 3 months)...”

The provider must report the results of those Root Cause Analyses to the co-ordinating commissioner on a monthly basis.

1. **How do you quality assure that your providers are complying with the national obligation to perform Root Cause Analyses of all confirmed cases of hospital associated thrombosis (HAT)?** (*Please tick as many boxes that apply)*

|  |  |
| --- | --- |
| **Method** | **Place an X as applicable** |
| Request real-time submission of Root Cause Analyses on completion |  |
| Request a monthly report of Root Cause Analyses |  |
| Request a quarterly report of Root Cause Analyses |  |
| Request an annual report of Root Cause Analyses |  |
| Request a face-to-face meeting to discuss Root Cause Analyses |  |
| Request made by other means not listed. (Please specify) |  |
| This information has yet to be requested |  |

1. **Between 1 April 2017 and 31 March 2018, has your CCG imposed any sanctions, verbal or written warnings on providers for failure to comply with the national obligation to perform Root Cause Analyses of all confirmed cases of HAT?** *(Please tick one box)*

|  |  |
| --- | --- |
| Yes |  |
| No |  |

**If ‘Yes’, please specify which providers your CCG has imposed sanctions, verbal or written warnings on between 1 April 2017 and 31 March 2018:**

|  |  |
| --- | --- |
| **Name of provider** | **Sanction, verbal or written warning?** |
|  |  |

**QUESTION 3 – VTE IN YOUR CCG AREA**

1. **Does your CCG have an estimate of the cost of VTE to the NHS locally (including cost of treatment, hospital bed days, sanctions and any litigation costs) for 2017/18?** *(Please tick one box)*

|  |  |
| --- | --- |
| Yes |  |
| No |  |

**If ‘Yes’, please specify the estimated cost:**

|  |
| --- |
| A robust financial estimate of health economy costs including additional bed days, community treatment and monitoring, extended sickness (cost to employers), sanctions and litigation does not exist at this time. |

**END**

**THANK YOU FOR YOUR RESPONSE**

Anticoagulation UK is the secretariat for the All Party Parliamentary Thrombosis Group. They employ Four Communications from grants received from the BMS - Pfizer Alliance and Bayer.